ESR1 and breast carcinoma: The results from the current study suggest that the combination of SM6Met with 4-OH-Tam could be a viable drug combination, which may potentially delay resistance and ameliorate the negative side effects associated with tamoxifen monotherapy while, in addition, ultimately inhibiting or preventing metastatic progression of ER+ breast cancer.